---
title: "Helicobacter pylori Serology and Resistant Hypertension: South African Cohort Protocol"
id: "plos-one-20-protocol-for-investigating-the-association-between-helicobacter-pylori-exposure"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-20-protocol-for-investigating-the-association-between-helicobacter-pylori-exposure"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362215"
published_at: "2026-11-06T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Helicobacter pylori Serology and Resistant Hypertension: South African Cohort Protocol
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-20-protocol-for-investigating-the-association-between-helicobacter-pylori-exposure
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0362215)
- **Published At:** 2026-11-06T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The protocol describes a cross-sectional observational study enrolling 200 adults (≥18 years) at a tertiary hospital in Cape Town to compare **resistant hypertension**, non-resistant hypertension, and normotension. - Target enrolment is 80 participants with resistant hypertension, 80 with non-resistant hypertension, and 40 normotensive controls; groups will be matched by age, sex, ethnicity and socioeconomic status where possible. - The primary exposure is serological evidence of **Helicobacter pylori** antigen-specific responses detected with the Pylori DuoTect® point-of-care assay, which measures antibodies to **CagA** and **FliD**. - Clinical phenotyping includes structured interviews, medication review, anthropometrics, and calibrated automated blood pressure measurement; eligibility and clinical data will be corroborated from medical records. - Biological sampling comprises blood, urine and saliva. Laboratory panels will include lipid profile, inflammatory markers, nitric oxide-related markers, homocysteine, insulin indices, complete blood count, ghrelin, multiplex cytokine profiling and flow cytometric immunophenotyping. - PAXgene® blood RNA samples will be retained for future exploratory transcriptomic analyses; saliva will undergo exploratory **H. pylori** antigen testing using kits validated for stool, not saliva, and results will not define the primary exposure variable. - Multivariable logistic regression will assess associations between seropositivity and hypertension phenotype, adjusting for demographic, lifestyle and clinical covariates; the study is powered to detect an absolute ~21% difference in seroprevalence between the two hypertensive groups. - The protocol explicitly notes that saliva antigen testing and future oral microbiome analyses are exploratory; no datasets have yet been generated and data will be made available upon study completion. - Limitations inherent to the cross-sectional design, pragmatic sample size, and the exploratory nature of some assays are acknowledged; the protocol frames results as hypothesis-generating for future mechanistic or interventional work.
## Clinical Analysis & Structured Key Points
Protocol for investigating the association between Helicobacter pylori exposure, antigen-specific serological responses, and resistant versus non-resistant hypertension in a South African cohort | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Reader Comments Figures Figures Abstract Background Hypertension is a leading contributor to cardiovascular morbidity and mortality, with poor control in low- and middle-income countries. Helicobacter pylori (H. pylori ) has been associated with hypertension through inflammatory, endothelial, metabolic and immune pathways, but data from sub-Saharan Africa, particularly in resistant hypertension, are limited. Methods This cross-sectional observational study will enrol 200 adults aged ≥18 at a tertiary academic hospital in Cape Town, South Africa: 80 with resistant hypertension, 80 with non-resistant hypertension and 40 with normotension. Participants will undergo standardised clinical assessment, blood pressure measurement, and collection of blood, urine and saliva. H. pylori exposure will be assessed using the Pylori DuoTect® point-of-care assay, which detects antibodies to CagA and FliD. Laboratory analyses will include lipid profile, inflammatory and nitric oxide-related markers, homocysteine, insulin indices, complete blood count, ghrelin, multiplex cytokine profiling and flow cytometric immunophenotyping. PAXgene® blood RNA samples will be retained for future exploratory analyses. Saliva will undergo exploratory H. pylori antigen testing using CerTest® kits, which are validated for stool rather than saliva. Saliva analysis will be exploratory, and results will not define the primary H. pylori exposure variable. Remaining saliva will be kept for potential future oral microbiome analyses not defined in this protocol. Multivariable logistic regression will evaluate associations between H. pylori exposure and hypertension phenotype, adjusting for demographic, lifestyle, and clinical covariates. Discussion To our knowledge, this will be the first African study to integrate point-of-care H. pylori serology with detailed clinical, inflammatory, metabolic, and immunological profiling across resistant hypertension, non-resistant hypertension and normotension. Findings may clarify biological pathways linking H. pylori exposure to blood pressure dysregulation and inform future mechanistic and interventional studies. Citation: Mennen MC, Zulu MZ, Mabatha KC, Baguma R, Skelem S, Mbundwini NN, et al. (2026) Protocol for investigating the association between Helicobacter pylori exposure, antigen-specific serological responses, and resistant versus non-resistant hypertension in a South African cohort. PLoS One 21(11): e0362215. https://doi.org/10.1371/journal.pone.0362215 Editor: Raja Singh Paulraj, Marshall University, UNITED STATES OF AMERICA Received: February 19, 2026; Accepted: October 21, 2026; Published: November 6, 2026 Copyright: © 2026 Mennen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion. Funding: This research is funded through a grant to Prof Ntobeko A. B. Ntusi from South African Medical Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: The authors have declared that no competing interests exist. Introduction Hypertension and chronic infections Hypertension underlies many prevalent cardiovascular diseases worldwide and remains a global health priority, affecting over 32% of women and 34% of men, and contributing to more than 8.5 million deaths annually [ 1 , 2 ]. Between 1990 and 2019, the number of adults living with hypertension doubled to 1.3 billion, with the steepest growth occurring in low- and middle-income countries (LMICs) [ 1 ]. In 2019, 82% of all people with hypertension in the world, which amounts to over 1 billion people, lived in LMICs [ 1 ]. Fewer than half of people receiving treatment for hypertension, globally, achieve blood pressure control, with global control rates at only 23% in women and 18% in men by 2019 [ 1 ]. In sub-Saharan Africa, control rates remained below 13%, showing little improvement since 1990, and a stark contrast to control rates of up to 60% in high-income countries [ 1 ]. Poorly controlled or treatment-resistant hypertension is associated with a substantially greater burden of target-organ damage and adverse cardiovascular and renal outcomes, including myocardial infarction, stroke, heart failure, chronic kidney disease and premature mortality [ 3 , 4 ]. Resistant hypertension represents an important high-risk hypertension phenotype and is generally defined as blood pressure remaining above target despite treatment with three antihypertensive agents of different classes, including a diuretic, or requiring four or more agents to achieve control [ 4 ]. Its pathophysiology is multifactorial, with recognised contributors including sodium and fluid retention, renin-angiotensin-aldosterone system activation, sympathetic nervous system overactivity, endothelial dysfunction, arterial stiffness, obesity, chronic kidney disease, obstructive sleep apnoea and genetic risk factors [ 5 – 7 ]. Increasing evidence suggests that persistent inflammatory stimuli may contribute to blood pressure dysregulation and treatment-resistant hypertension, providing a rationale for investigating chronic infections in this population. Infectious agents associated with chronic and latent infection, including Mycobacterium tuberculosis (Mtb) , Plasmodium falciparum , human immunodeficiency virus (HIV), cytomegalovirus (CMV), herpes simplex virus (HSV) and Helicobacter pylori (H. pylori ), may increase the risk of hypertension and cardiovascular disease [ 8 – 11 ]. Chronic infections can induce persistent low-grade chronic inflammation, a key pathogenic driver of endothelial injury, vascular remodelling, oxidative stress, and altered metabolic and immune pathways involved in blood pressure regulation [ 12 ]. Helicobacter pylori and hypertension H. pylori is a highly prevalent chronic gastric pathogen that infects approximately half of the world’s population, with its main reservoir being the human stomach [ 13 ]. It is particularly prevalent in many LMICs, infecting 80–90% of individuals in some African countries [ 13 , 14 ]. H. pylori is a gram-negative, microaerophilic, flagellated bacterium that colonises the gastric mucosa and is transmitted primarily through the faecal-oral route [ 13 ]. However, oral-oral transmission is also possible [ 13 ]. Isolation of H. pylori in saliva and dental plaque has been reported [ 13 , 15 , 16 ]. H. pylori has adapted to the acidic environment of the human stomach by evolving a range of virulence mechanisms that allow it to withstand highly acidic conditions, colonise the gastric mucus layer, and adhere to epithelial cells [ 17 ]. These characteristics enable its effective colonisation of the gastric mucosa, facilitating long-term persistence and chronic gastric inflammation. Beyond its established roles in gastritis, peptic ulcer disease and gastric cancer, H. pylori has been linked to several extra-gastrointestinal conditions, including insulin resistance, metabolic syndrome, vascular inflammation, and cardiovascular disease. Multiple observational studies across Asia, the Middle East and Africa have reported positive associations between H. pylori infection and hypertension [ 18 – 22 ]. Similarly, meta-analyses have noted an increased risk of hypertension among individuals with H. pylori infection, with pooled odds ratios ranging from 1.3–1.4 [ 23 , 24 ]. A small interventional study conducted in Italy reported reductions in blood pressure following H. pylori eradication, offering preliminary support for causality, although its sample size and follow-up were limited [ 25 ]. Contrary to the growing body of evidence suggesting a positive association, there are a few studies that reported no association between H. pylori infection and hypertension [ 26 , 27 ]. The lack of consensus may be due to strain-specific pathogenicity, with virulence-associated strains such as CagA (cytotoxin-associated gene-A)-positive strains being more strongly linked to cardiovascular outcomes [ 28 ]. Duration of infection may also influence risk [ 29 ]. Mechanistic hypotheses Several interrelated biological pathways provide plausible mechanisms by which H. pylori may contribute to hypertension. Virulence-associated strains, particularly CagA-positive strains, may trigger local and systemic inflammation, endothelial dysfunction, and immune cross-reactivity. Anti-CagA antibodies have been shown to cross-react with vascular wall antigens, suggesting a possible autoimmune mechanism [ 30 ]. FliD (flagellar hook-associated protein 2) is an essential component of the H. pylori flagellar apparatus and is required for functional flagella, motility and effective colonisation of the gastric mucosa [ 31 ]. FliD is highly immunogenic and has demonstrated high sensitivity and specificity as a serological marker of H. pylori infection [ 32 ]. The Pylori DuoTect® assay used in this study detects antibodies to the CagA and FliD antigens, with FliD serving as a marker of H. pylori exposure and CagA providing complimentary information regarding exposure to an established virulence-associated antigen. Although, to our knowledge, there is no direct evidence linking FliD itself to cardiovascular disease, its role in motility and colonisation provides a biologically plausible link to persistent bacterial exposure and sustained antigenic stimulation [ 31 ]. This is relevant to hypertension, in which chronic inflammatory and oxidative pathways contribute to endothelial dysfunction, vascular remodelling and impaired nitric oxide bioavailability [ 33 , 34 ]. Prospective data from the REGARDS study have linked circulating inflammatory cytokines to incident hypertension, while the CRIC study demonstrated associations between inflammatory biomarkers and apparent treatment-resistant hypertension [ 35 , 36 ]. Studies conducted in diverse population groups have reported associations between H. pylori infection and elevated total cholesterol, low-density lipoprotein (LDL) cholesterol, and inflammatory markers, each of which contributes to increased peripheral vascular resistance and heightened hypertension risk [ 12 , 37 , 38 ]. Chronic inflammatory activation is associated with increased leukocyte counts, homocysteine, fibrinogen, CRP, IL-6 and TNF- α, promoting endothelial dysfunction and altered vascular tone [ 39 ]. Inflammation-associated oxidative stress may further reduce nitric oxide (NO) bioavailability, affecting NO functions in vasodilation and vascular homeostasis, including inhibition of platelet aggregation and suppression of smooth muscle cell proliferation [ 40 ]. Ghrelin, a hormone predominantly secreted by the stomach that is gastroprotective and plays key roles in gastric mucosal defence, appetite regulation and weight regulation may be disrupted by H. pylori infection [ 41 ]. Altered ghrelin synthesis can impair insulin sensitivity and glucose uptake, potentially contributing to insulin resistance and metabolic syndrome, both recognised drivers of hypertension [ 41 ]. A high dietary salt intake may also promote H. pylori colonisation and exacerbate gastric mucosal injury, further amplifying hypertension risk [ 42 ]. Study rationale Previous observational studies and meta-analyses have reported associations between H. pylori infection and hypertension; however, findings have been inconsistent, and most studies have not assessed resistant hypertension specifically. There is a critical paucity of data from sub-Saharan Africa regarding the pathogenic relationship between H. pylori exposure and hypertension, particularly resistant hypertension. To date, no African studies have assessed serological markers of exposure to H. pylori virulence-associated antigens, including CagA (cytotoxin-associated gene A), or FliD (flagellar hook-associated protein 2) in individuals with resistant hypertension using validated point-of-care assays, or integrated analyses of inflammatory pathways and immunophenotyping in the context of H. pylori exposure. Given the high regional burden of H. pylori infection and both resistant and non-resistant hypertension, addressing this evidence gap is of substantial public health importance. This study will examine associations between H. pylori exposure and hypertension across resistant hypertensive, non-resistant hypertensive and normotensive adults, while exploring the inflammatory, immunological, metabolic and microbial pathways that may underlie these associations. Accordingly, this study aims to (1) investigate the association between H. pylori exposure (including CagA and FliD seropositivity) and both resistant and non-resistant hypertension in a South African cohort; (2) explore biological mechanisms linking exposure to blood pressure dysregulation; and (3) characterise clinical, biochemical, microbial, and immunological features in exposed versus unexposed individuals. Materials and methods Study objectives The primary objective of this study is to explore associations between H. pylori exposure, specifically serological evidence of exposure to CagA or FliD antigens, and hypertension phenotypes, including resistant hypertension, non-resistant hypertension and normotension. We hypothesise that prevalence of both CagA and FliD seropositivity will be highest in resistant hypertensive participants compared to non-resistant hypertensive and normotensive participants. The null hypothesis will be rejected if inter-group differences reach statistical significance (p < 0.05). Secondary objectives include characterisation of clinical, biochemical, and immunological differences by H. pylori exposure status, and identifying potential mechanistic links between exposure and blood pressure dysregulation. Study design and sample size This cross-sectional observational study will be conducted at Groote Schuur Hospital (GSH), a tertiary/quaternary academic hospital affiliated with the University of Cape Town, South Africa ( Fig 1 ). Adult participants, aged ≥18, will be recruited from the hypertension clinic, general medical wards, and the hospital staff cohort. Participants will be classified into one of three groups: resistant hypertension, non-resistant hypertension, or normotension. Participants in the hypertensive groups will be adults with a pre-existing clinical diagnosis of hypertension who are receiving antihypertensive treatment at the time of recruitment. Resistant hypertension will be defined as elevated blood pressure despite concurrent use of three or more antihypertensive medications from different classes, including a diuretic, or adequate blood pressure control on more than three agents [ 4 ]. Non-resistant hypertension will be defined as adequate blood pressure control on fewer than or equal to three antihypertensive agents. Normotension is defined as the absence of hypertension and no use of antihypertensive therapy. Download: PNG larger image TIFF original image Fig 1. Overview of the study design and protocol workflow. Adult participants will be recruited from a tertiary academic hospital hypertension clinic, general medical wards, and a hospital staff cohort. Following confirmation of eligibility, participants will be enrolled into one of three groups: resistant hypertension (n = 80), non-resistant hypertension (n = 80), or normotensive controls (n = 40). All participants will undergo structured clinical assessment and biological sampling, including blood, saliva, and urine collection. H. pylori exposure will be assessed using the Pylori DuoTect® point-of-care assay, which detects antibodies against CagA and FliD. Downstream analyses will include clinical biochemistry, inflammatory and cytokine profiling, ghrelin quantification, potential future proteomic and transcriptomic analyses, immunophenotyping of peripheral blood mononuclear cells, oral H. pylori antigen detection, potential exploratory oral microbiome characterisation from saliva, and assessment of albumin-creatinine ratio from urine. The study integrates clinical, microbial, and immunological data to investigate associations between H. pylori exposure and resistant versus non-resistant hypertension. https://doi.org/10.1371/journal.pone.0362215.g001 The recruitment target was initially determined pragmatically, based on anticipated recruitment capacity and the exploratory nature of the study. Published meta-analyses have reported modest associations between H. pylori infection and hypertension, with pooled odds ratios of approximately 1.3 [ 23 , 24 ]. However, these estimates relate to hypertension in general and do not directly inform the primary comparison between resistant and non-resistant hypertension, for which no reliable prior prevalence or effect-size estimates were available. The planned sample therefore comprises 200 participants: 80 with resistant hypertension, 80 with non-resistant hypertension and 40 normotensive controls. A detectable-effect-size analysis was performed in R version 4.5.2 using a two-sample comparison of proportions, a two-sided α of 0.05 and 80% power. With 80 participants in each hypertensive group, the study is powered to detect an absolute between-group difference in seroprevalence of approximately 21%. The normotensive group will serve as a secondary comparison group for exploratory analyses across hypertension phenotypes. During recruitment we will match study groups by age, sex, ethnicity and socioeconomic status, and eligibility will be assessed as per the predefined inclusion and exclusion criteria ( Table 1 ). Consecutive eligible patients will be approached during routine clinic visits. This means that all patients attending the relevant clinical services during recruitment periods who meet the eligibility criteria will be approached sequentially for participation, rather than being selectively recruited according to clinical characteristics. Written informed consent will be obtained from all participants in accordance with ethics approval. Consent forms will be witnessed by a study staff member and completed in duplicate, with one signed copy provided to the participant. Download: PNG larger image TIFF original image Table 1. Inclusion and exclusion criteria for study participants. https://doi.org/10.1371/journal.pone.0362215.t001 Study procedures Following informed consent, participants will undergo a structured clinical assessment using a case report form approved by the Human Research Ethics Committee. Data collected will include demographics (age, sex, ethnicity), anthropometrics (height, weight), lifestyle factors (smoking, alcohol use, dietary salt intake), comorbidities (hypertension, diabetes, dyslipidaemia, respiratory disease, GI conditions, HIV status), medication history (antihypertensives, statins, proton-pump inhibitors, antibiotics, antiretrovirals, non-steroidal anti-inflammatory drugs and steroids), past medical and surgical history, family history of cardiovascular disease, and vital signs (blood pressure and heart rate). Information will be collected through participant interviews conducted by trained nurses and doctors fluent in English, Afrikaans and isiXhosa, followed by review of their medical records to verify clinical information. Blood pressure will be measured using calibrated automated
## Related Clinical Research

- [Lifestyle Changes May Help Prevent Multimorbidity In Prediabetes](https://medichelpline.com/clinical-feed/medical-news-today-23-diet-weight-loss-and-150-minutes-of-exercise-may-protect-against-chronic.md)
- [Moving Forward: The Future of GLP-1 Therapies](https://medichelpline.com/clinical-feed/endocrine-news-18-moving-forward-the-future-of-glp-1-therapies.md)
- [Medicinal Plants and Diabetic Nephropathy: Phytochemicals, Mechanisms, and Therapeutic Potential](https://medichelpline.com/clinical-feed/frontiers-in-immunology-2-medicinal-plants-in-diabetic-nephropathy-bioactive-compounds-mechanisms-and.md)
- [Machine learning and deep learning prediction of hypertension and key risk factors in Bangladesh](https://medichelpline.com/clinical-feed/plos-one-12-machine-learning-and-deep-learning-based-prediction-of-hypertension-and.md)
- [Multimodal extraction of heart disease risk factors from free-text and structured records using Li](https://medichelpline.com/clinical-feed/plos-one-0-leveraging-free-text-clinical-records-for-heart-disease-classification-through.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.